基质金属蛋白酶14与血浆激肽释放酶1可能成为脓毒症诊断与治疗的潜在生物标志物:一项蛋白质组学与生物信息学分析
该横断面观察研究纳入2019年1月至12月西南医科大学附属医院急诊科EICU收治的12例脓毒症患者与9例健康志愿者,采集外周血行蛋白组学质谱分析,采用数据非依赖采集技术获取蛋白表达数据,经IDEP2在线工具完成ID转换、均一化验证可比性及主成分分析剔除离群数据后,以P<0.05且log2FC>1或log2FC<-1为差异有统计学意义筛出差异蛋白。共筛选出125个差异蛋白,其中99个上调、26个下调;GO富集分析发现这些蛋白主要为细胞外蛋白,具有细胞调控功能和催化功能,参与生物调节、代谢过程和免疫过程;KEGG通路分析提示其参与氨基酸、碳水化合物代谢及免疫相关通路。STRING网站PPI分析显示关键蛋白包括基质金属蛋白酶14(MMP14)、纤蛋白1(FBLN1)、血浆激肽释放酶1(KLKB1)等,最终筛选出与炎症和免疫密切相关的MMP14与KLKB1,二者均可能是脓毒症早期诊断与治疗的潜在新靶点。结论认为MMP14与KLKB1可能成为脓毒症诊断、治疗和预后的潜在生物标志物。
要点
- 研究纳入12例脓毒症患者与9例健康志愿者,采集外周血行蛋白组学质谱分析,采用数据非依赖采集技术获取各蛋白表达数据。
- 差异蛋白筛选标准为P<0.05且log2FC>1或log2FC<-1,共筛出125个差异蛋白,其中99个上调、26个下调。
- GO富集分析显示差异蛋白主要为细胞外蛋白,具有细胞调控功能与催化功能,参与生物调节、代谢过程及免疫过程。
- KEGG通路分析提示差异蛋白参与氨基酸、碳水化合物代谢及免疫相关通路;PPI分析显示关键蛋白包括MMP14、FBLN1、KLKB1等。
- 最终筛选出与炎症和免疫密切相关的MMP14与KLKB1,二者均可能是脓毒症早期诊断与治疗的潜在新靶点,也可能成为诊断、治疗和预后的潜在生物标志物。
适用人群与场景
- 2019年1月至12月在西南医科大学附属医院急诊科急诊重症监护病房(EICU)招募的12例脓毒症患者与9例健康志愿者,采集外周血行蛋白组学分析。
诊断标准与关键阈值
- 差异蛋白判定标准:数据经IDEP2在线工具均一化验证可比性并以主成分分析剔除离群数据后,P<0.05且log2fold change(FC)>1或log2FC<-1视为差异有统计学意义。
研究设计与关键结果
- 研究类型为横断面观察研究,纳入12例脓毒症患者与9例健康志愿者,两组外周血经蛋白组学质谱分析,数据均一化后显示可比。
- 共筛选出125个差异蛋白,其中99个上调、26个下调。
- GO富集分析发现差异蛋白主要为细胞外蛋白,具有细胞调控功能与催化功能,参与生物调节、代谢过程及免疫过程。
- KEGG通路分析提示差异蛋白参与氨基酸、碳水化合物代谢及免疫相关通路。
- STRING网站PPI分析显示关键蛋白包括基质金属蛋白酶14(MMP14)、纤蛋白1(FBLN1)、血浆激肽释放酶1(KLKB1)等,最终筛选出与炎症和免疫密切相关的MMP14与KLKB1,二者均可能是脓毒症早期诊断与治疗的潜在新靶点。
证据类型、等级与局限
- 证据类型:横断面观察研究(蛋白质组学与生物信息学分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为MMP14与KLKB1可能成为脓毒症诊断、治疗和预后的潜在生物标志物,二者均可能是脓毒症早期诊断与治疗的潜在新靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze protein profiles in septic patients, and to find potential new targets for the diagnosis and treatment of sepsis.
METHODS: A cross sectional observational study was conducted. From January to December 2019, 12 septic patients and 9 healthy volunteers were recruited in the emergency intensive care unit (EICU) of the emergency department of the Affiliated Hospital of Southwest Medical University. The peripheral blood of the two groups was collected for protein mass spectrometry analysis, and the data-independent acquisition technology was used to obtain the expression data of each protein. The obtained data was imported into the online network tool Integrated Differential Expression and Pathway analysis (IDEP2), the data underwent ID converted and were homogenized to verify their comparability, and then principal component analysis was used to eliminate outlier data. Then data with P < 0.05, log2fold change (FC) > 1 or log2FC < -1 were considered to have a statistically significant difference, and the differential proteins were screened out. On the DAVID website, the screened differential proteins would be analyzed by gene ontology (GO), and the biological process, cellular components, and molecular function of the proteins would be analyzed. Protein enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed. Protein-protein interaction (PPI) analysis was performed through the Search Tool for the Retrieval of Interacting Genes Database (STRING) website to find closely related proteins.
RESULTS: The data in this study were shown to be comparable after normalization. A total of 125 differential proteins were screened, of which 99 were up-regulated and 26 were down-regulated. GO enrichment analysis discovered that these proteins were mainly extracellular, with cellular regulatory functions and catalytic functions involved in biological regulation, metabolic process and immune process. KEGG pathway analysis suggested that these proteins were involved in amino acid, carbohydrate metabolism and immune-related pathways. PPI analysis showed that key proteins included matrix metalloproteinase 14 (MMP14), fibulin 1 (FBLN1), plasma kallikrein 1 (KLKB1), etc., and finally screened out MMP14 and KLKB1, which were closely related to inflammation and immunity. Both might be potential new targets for early diagnosis and treatment of sepsis.
CONCLUSIONS: MMP14 and KLKB1 may be potential biomarkers for the diagnosis, treatment and prognosis of sepsis.
参考来源
- Feng L, Liu Y, Chen M, et al. [Matrix metalloproteinase 14 and plasma kallikrein 1 may be potential biomarkers in the diagnosis and treatment of sepsis: a proteomics and bioinformatics analysis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36100402. doi:10.3760/cma.j.cn121430-20210706-01011
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。